BLOG

FDA Warning on Xylazine: Mitigating Human Risk

FDA Warning on Xylazine: Mitigating Human Risk

FDA Warning on Xylazine: Mitigating Human Risk  | by: Sumeet Singh, Founder & Chairman | Article Posted: November 6, 2023 | The U.S. Food and Drug Administration (FDA) has issued a warning regarding mitigating risks from human Xylazine exposure. FDA has not...

read more
Industry News
Optum Rx & NABP DDA Lawsuit Update

Optum Rx & NABP DDA Lawsuit Update

Optum Rx’s requirement for their network pharmacies to only purchase prescription drug and diabetic testing supplies from Accredited wholesalers has caused significant disruption and controversy since its implementation in August 2016. The requirement spurred two separate lawsuits. The second, which continues in full force, has a recent amended complaint – and Pharma Solutions has unique insight into the lawsuit’s developments.

read more
Optum Rx & NABP DDA Lawsuit Update

Shipping Office Stock vs. Prescriptions: $15M Case Study for Omnicare

Omnicare, a leading provider of closed-door pharmacy services, agreed to pay more than a $15 million civil penalty for allowing opioids and other controlled substances to be dispensed without a valid prescription. The fine zeroes in on a common issue amongst pharmacies – discerning between office stock and shipping pursuant to a prescription.

read more
PBMs Turn Up the Pressure on Diabetic Test Strip Reimbursements

COVID-19 Shortages: Boom or Bust for Business?

This week, we explore how to legally and ethically navigate supplying products during the pandemic. It is the wild west in the hospital supply business – from illegal import practices and price-gouging to ingenious manufacturing and extra hours.

read more

Email Newsletter